Regeneron Pharmaceuticals

Bull case

Regeneron Pharmaceuticals is supported by a durable franchise in Dupixent and Eylea, both of which have strong real-world efficacy, long-term safety, and room for continued expansion, while new upside can also come from faster adoption of high-dose aflibercept and the Eylea HD pre-filled syringe approval expected this qtr. Its fully integrated model and partnerships with Sanofi, Bayer, and Roche diversify commercialization risk and broaden development leverage, while ongoing negotiations with Sanofi could improve collaboration economics and add further upside. The company’s pipeline across oncology, inflammatory diseases, and genetic medicine, plus a $3.4B buyback and catalysts including the 4Q26 cemdisiran gMG PDUFA and Factor XI data expected in 1H27, reinforce a constructive fundamental outlook.

Bear case

• Regeneron Pharmaceuticals is facing a weakening fundamental profile as Eylea sales erode over time from biosimilar entrants, new biologic competition, and IRA pressure, while the company still depends heavily on a franchise the source says may lose market share.
• Its growth outlook is further pressured by increasing competition for Dupixent, possible setbacks in new indications, and clinical and regulatory risk across oncology and other pipeline programs, including the fianlimab Phase III miss in 1L metastatic melanoma with HR of 0.845 and p=0.0627.
• Those execution issues, along with prior missteps, raise broader concerns about management strategy and the durability of future innovation, making the stock’s downside risks look more pronounced than the upside.